Clinical evaluation and performance evaluation: differing evidence structures

1. Key takeaways

A Hong Kong, China listing file requires different evaluation reports for the two device families. A general medical device (GMD) is supported by a clinical evaluation report; an in vitro diagnostic medical device (IVDMD) is supported by a performance evaluation report. The first answers whether the device is safe and effective when used on people, and its evidence hierarchy runs from clinical data to data on an equivalent device to the scientific literature. The second answers whether the device measures accurately, and its evidence structure has two parts, analytical performance and clinical performance. Using one report to cover both device families, or writing the performance evaluation of an IVD as though it were a clinical evaluation, is a common error.

The two reports differ in object, in evidence type and in the way the reviewer reads them, so the drafting team should be organised by device family rather than by document template.

• Device family decides report type. GMD goes to a clinical evaluation report, IVDMD to a performance evaluation report, with no mixing.
• The evidence chains are not interchangeable. Patient outcomes on one side, measurement reliability on the other.
• Self-testing is a separate evidence obligation. Lay-user variation has to be covered where the device is intended for home use.
• Foreign reports can be reused, but not bare. Reuse needs a localisation layer covering population, environment and label language.
• Report depth must match the class. A report written for a higher class does not strengthen a lower-class file, and the reverse guarantees a supplementary request.

2. Legal basis

The requirement originates in the MDD overview of the listing process, uploaded on 8 October 2025, which lists the clinical evaluation report and the performance evaluation report among the documents required for an application. The detail sits in GN-02 for Class II, III and IV general medical devices and in GN-06 for Class B, C and D in vitro diagnostic devices. TR-004 supplies the safety and performance principles that both reports address, and TR-006 supplies the classification of in vitro diagnostic devices, which determines the depth of evaluation expected.

The classification reference is not a formality. TR-006 classifies in vitro diagnostic devices by intended use as well as by other dimensions, and the class assigned determines how much analytical and clinical performance evidence the reviewer expects to see. A report written before classification is settled tends to be either overbuilt or underbuilt.

3. Expert insights

The object of evaluation determines the structure of the report. For a general device the object is the patient outcome, and the evidence comes from clinical trials, comparison with an equivalent device and the scientific literature. For an in vitro diagnostic device the object is the reliability of the test result, and the evidence comes from analytical performance studies such as precision, accuracy, limit of detection and linear range, together with clinical agreement studies. A report that describes analytical performance in the vocabulary of clinical benefit reads as a category error to a reviewer who works in the IVD framework.

An IVD evaluation must cover the self-test scenario. Where the product is intended for home use or self-testing, the performance evaluation has to cover the operational variation introduced by lay users, not only the performance achieved by trained laboratory staff. MDD maintains dedicated pages on home blood glucose meters and test strips, on influenza rapid antigen tests and on COVID-19 rapid antigen tests, which shows that these product groups carry specific evaluation expectations. Applicants in these categories should treat the dedicated page as part of the requirement set.

Foreign evaluation reports can be reused, but they need a localisation layer. Existing clinical or performance data may be reused, provided that explanations are added on the Hong Kong, China population, the use environment and the label language. Hong Kong, China uses the Asian Medical Device Nomenclature, and the description of the sample population should stay as close to local reality as the underlying studies allow. This is a practical estimate of what review practice expects, not a fixed threshold.

The report has to match the class. The higher the class, the greater the depth and independence expected of the evaluation. Applying a report written for a high-class device to a low-class product earns nothing, while applying a low-class report to a high-class product reliably produces a request for further information. The report is read against the class, not in isolation.

Conclusion and checklist must speak with one voice. The conclusion of the evaluation report is one of the places the Essential Principles checklist points to. If the report concludes that a claim is supported only under stated conditions, the checklist entry has to say the same thing, and the label has to reflect it as well.

4. Practical recommendations

• Select the report type by device family. General medical devices use a clinical evaluation report, in vitro diagnostic devices use a performance evaluation report, and the two are never substituted for each other.
• Split the IVD report into two volumes. One volume for analytical performance and one for clinical performance, so that the reviewer can navigate without searching.
• Add lay-user studies for self-test products. Include precision and interpretation agreement data from non-professional operators in the evaluation.
• Keep a data reuse schedule. Mark which data come from foreign studies and which are local supplements for Hong Kong, China, so that the reviewer can see the provenance at a glance.
• Re-read the report against the class decision. Confirm that the depth of evidence is proportionate before the file leaves the building.

5. Verification checklist

• □ The report type has been fixed by device family, clinical evaluation or performance evaluation.
• □ The depth of the report matches the classification of the product.
• □ The IVD report contains both analytical performance and clinical performance parts.
• □ Self-test products cover studies with non-professional users.
• □ Foreign data and Hong Kong, China local supplementary data are clearly distinguished.
• □ The conclusions of the report match the references in the Essential Principles checklist.

Regulatory information verified as at 29 October 2026. The legislation, guidance and effective dates described in this article are limited to the content published by the official sources listed under legal basis on that date; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team prepares MDACS-compliant dossiers, coordinates evidence of reference approvals and ISO 13485 certificates, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com